Est. 2001·3,000+ placements · six offices · four regions

Company signals

Nasus Pharma

2 signals in the current window, with MitchelLake's leadership read on each.

Last updated

Market context: MitchelLake's Talent Market Index sits at 122.7 (Hot), up 17.8 on the prior month; Americas hiring signal is running rising (+34.4pts).

Nasus Pharma: 1 signal in the last 90 days; 2 tracked across 145 days.

Signals at Nasus Pharma

Leadership Change

Americas

Nasus Pharma appointed Brendan O'Grady, a pharma industry veteran, as Chief Executive Officer

Leadership read: A change at the top rarely stays at the top. Nasus Pharma's move reshapes the layer beneath it in the sector as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

curated · 2026-08-17 · context →

Product Launch

Americas

Nasus Pharma reports positive Phase 2 results for NS002 epinephrine delivery system, with pivotal study planned for Q4 2026

Leadership read: The Phase 2 result commits Nasus Pharma to a materially different operating posture than a clinical-stage company running exploratory trials. A pivotal study in Q4 2026 means the firm now has a defined regulatory submission pathway, which forces concurrent build-out across clinical operations, regulatory affairs, and, critically, the commercial infrastructure needed to compete in a category where EpiPen holds deep payer and formulary entrenchment. The competitive claim (statistically significant improvement in early absorption) is the kind of differentiation argument that has to be stress-tested in payer conversations, not just clinical dossiers. The related signals available across the 12 product-launch comparables tracked in this window are drawn from fintech, defense, consumer electronics, and pharma, only Novo Nordisk's Phase 3 failure sits in the same corridor, and that is a cautionary data point rather than a comparable advance. The honest read: the pharma-specific pattern density here is thin, which limits the market-framing. What is visible is that specialty drug delivery companies reaching pivotal-stage milestones tend to accelerate commercial and regulatory investment well ahead of FDA submission, not after. Companies at this stage of the epinephrine / emergency-medication corridor consistently face rising demand for regulatory leadership with FDA device-drug combination experience, market-access and formulary strategy capability, and clinical operations talent able to execute a compressed pivotal timeline while preparing a parallel commercial case.

curated · 2026-03-25 · context →

Executive hires, departures and board changes at Nasus Pharma

Every leadership-change and senior-hiring signal observed at Nasus Pharma, newest first, each dated and linked to the source record.

Nasus Pharma signals in the last 90 days

1 public signal observed since 21 July 2026, by type.

More signals across Americas

Product Launch · Americas

Forter →

Forter launched its Agentic Commerce Engine on October 13, 2026, bundling fraud management for agent-driven traffic, headless agentic checkout orchestration and an AI activity dashboard for merchants ahead of holiday peak.

Product Launch · Americas

Masimo →

Masimo announced FDA clearance of its smartSET pulse oximetry platform, which adds atrial fibrillation (AFib) detection alongside previously cleared AI-enabled opioid-induced respiratory depression (OIRD) detection.

Product Launch · Americas

Lucid Poker →

Lucid Poker, an Austin, Texas mobile-first poker training app, launched Cardle, a free daily poker quiz accessible on the web at cardle.poker with no sign-up or download required.

Product Launch · Americas

REVION (레비온) →

Korean esports performance-tech startup REVION is launching its REVION Grip gaming glove on Kickstarter on 14 October 2026, its first global consumer product release and first test of US market demand.

Product Launch · Americas

FF EAI Robotics (FFR) →

FF EAI Robotics (FFR) and FF jointly launched FF Nova, an entry-level embodied AI humanoid robot priced below $2,500 in the U.S., alongside FF Nova Mini, a Physical AI Spark Program curriculum, a Nova reinforcement learning developer program, and developer community recruitment.

Product Launch · Americas

Mellow Sleep →

Mellow Sleep, a DTC sleep brand that reached about $130M revenue in its first year, is making its physical retail debut in 550 Target stores from October 18, rolling out nationwide by year-end. Its five-product collection ranges from $39.99 to $129.99.

Where Nasus Pharma's market lands in our work

Weekly briefing

Track companies like Nasus Pharma — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

MitchelLake is a global executive search and advisory firm covering AI, innovation and expansion leadership for companies navigating transformation and change across industries, from startups and scale-ups to private-equity-backed and enterprise organisations. 3,000+ C-suite, specialist and board placements since 2001.

Discuss leadership at a moment like this →
Data period
25 Mar 2026 – 17 Aug 2026 · 2 signals for this company
Publisher
MitchelLake

Last updated